US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

190.00

-1.9900-1.04%

Volume:405.03K

Turnover:77.03M

Market Cap:10.93B

PE:31.58

High:192.17

Open:191.00

Low:189.20

Close:191.99

52wk High:203.89

52wk Low:127.04

Shares:57.55M

Float Shares:48.77M

Volume Ratio:1.48

T/O Rate:0.83%

Dividend:0.87

Dividend Rate:0.46%

EPS(TTM):6.02

EPS(LYR):5.15

ROE:17.94%

ROA:9.25%

PB:5.80

PE(LYR):36.88

Loading ...

Overview Company News Filings

Crane 1Q Profit Soars on Higher Revenue

Crane Co reports results for the quarter ended March 31 - Earnings Summary

Crane Holdings Q1 Adj. EPS $1.39 Beats $1.31 Estimate, Sales $557.60M Beat $547.96M Estimate

BRIEF-Crane Company Q1 Sales USD 557.6 Million Vs. IBES Estimate USD 548 Million

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

North American Morning Briefing: Stock Futures Fall Ahead of New Data

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

Crane (CR) Q1 Earnings Report Preview: What To Look For

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

1 Profitable Stock on Our Watchlist and 2 to Brush Off

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Allegion Gears Up to Post Q1 Earnings: Here's What to Expect

Crane Company (CR) Receives a Rating Update from a Top Analyst

Crane, Kennametal, International Paper, Lennar, and KB Home Shares Plummet, What You Need To Know

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":190,"timestamp":1755720000000,"preClose":191.99,"halted":0,"volume":405029,"delay":0,"floatShares":48765462,"shares":57546840,"eps":6.016852,"marketStatus":"Pre-Mkt","change":-1.99,"latestTime":"08-21 06:56:52 EDT","open":191,"high":192.17,"low":189.2,"amount":77029152.37278,"amplitude":0.01547,"askPrice":302.1,"askSize":100,"bidPrice":187,"bidSize":1,"shortable":3,"etf":0,"ttmEps":6.016852,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1755783000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":190,"dividendRate":0.004579,"postHourTrading":{"tag":"盘后","latestPrice":190,"preClose":190,"latestTime":"16:36 EDT","volume":73348,"amount":13936120,"timestamp":1755722210232},"volumeRatio":1.479855313991063,"impliedVol":0.2846,"impliedVolPercentile":0.0924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","floatShares":48765462,"roa":"9.25%","roe":"17.94%","lyrEps":5.152097,"volumeRatio":1.479855313991063,"shares":57546840,"dividePrice":0.87,"high":192.17,"amplitude":0.01547,"preClose":191.99,"low":189.2,"week52Low":127.04,"pbRate":"5.80","psRate":"4.91","week52High":203.89,"institutionHeld":0.6875,"latestPrice":190,"committee":-0.980198,"eps":6.016852,"divideRate":0.004579,"volume":405029,"delay":0,"ttmEps":6.016852,"open":191,"prevYearClose":151.75,"prevWeekClose":189.19,"prevMonthClose":195.77,"prevQuarterClose":189.89,"fiveDayClose":198.45,"twentyDayClose":188.49,"sixtyDayClose":170.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CR\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-29","defaultRemindTime":1756474200000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-08-29","currency":"USD","dateTimestamp":1756440000000,"payDate":"2025-09-10"},{"market":"US","date":"2025-07-28","symbol":"CR","fiscalQuarterEnding":"2025/06","expectedEps":1.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753675200000,"reportTimeType":"post","actualEps":1.49},{"date":"2025-05-30","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-11"},{"market":"US","date":"2025-04-28","symbol":"CR","fiscalQuarterEnding":"2025/03","expectedEps":1.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745812800000,"reportTimeType":"post","actualEps":1.39},{"date":"2025-02-28","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CR\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":"2017-02-28","paymentDate":"2017-03-09","value":0.33,"currency":"USD"},{"executeDate":"2017-05-26","recordDate":"2017-05-31","paymentDate":"2017-06-09","value":0.33,"currency":"USD"},{"executeDate":"2017-08-29","recordDate":"2017-08-31","paymentDate":"2017-09-08","value":0.33,"currency":"USD"},{"executeDate":"2017-11-29","recordDate":"2017-11-30","paymentDate":"2017-12-08","value":0.33,"currency":"USD"},{"executeDate":"2018-02-27","recordDate":"2018-02-28","paymentDate":"2018-03-09","value":0.35,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.7778,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7778,"analysts":9,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CR","date":"2025-08-20","current":31.405395,"percent":0.722313,"low":8.74154,"twenty":14.045193,"median":24.891934,"eighty":34.721243,"high":224.415426,"avg":33.199356,"sd":39.04137,"marketCap":11048417811},"quantilePoints":[{"date":"2020-08-21","current":87.719084,"twenty":14.813662,"median":19.570486,"eighty":28.081529,"marketCap":3289465651},{"date":"2020-08-28","current":90.040104,"twenty":14.83771,"median":19.594842,"eighty":28.170784,"marketCap":3376503903},{"date":"2020-09-04","current":88.260655,"twenty":14.871894,"median":19.605519,"eighty":28.267865,"marketCap":3309774577},{"date":"2020-09-11","current":84.237554,"twenty":14.936445,"median":19.626415,"eighty":28.310525,"marketCap":3158908274},{"date":"2020-09-18","current":81.978428,"twenty":15.011846,"median":19.656053,"eighty":28.373051,"marketCap":3074191042},{"date":"2020-09-25","current":76.779343,"twenty":15.041272,"median":19.669528,"eighty":28.409968,"marketCap":2879225359},{"date":"2020-10-02","current":76.965025,"twenty":15.066218,"median":19.682881,"eighty":28.47471,"marketCap":2886188419},{"date":"2020-10-09","current":80.137085,"twenty":15.081973,"median":19.70422,"eighty":28.560476,"marketCap":3005140696},{"date":"2020-10-16","current":84.253027,"twenty":15.124703,"median":19.713849,"eighty":28.62779,"marketCap":3159488529},{"date":"2020-10-23","current":85.320697,"twenty":15.162424,"median":19.729877,"eighty":28.703268,"marketCap":3199526125},{"date":"2020-10-30","current":136.527006,"twenty":15.223621,"median":19.752233,"eighty":28.737446,"marketCap":2948983334},{"date":"2020-11-06","current":142.122596,"twenty":15.260409,"median":19.772138,"eighty":28.792366,"marketCap":3069848070},{"date":"2020-11-13","current":165.258207,"twenty":15.260409,"median":19.790516,"eighty":28.85843,"marketCap":3569577265},{"date":"2020-11-20","current":177.390952,"twenty":15.260409,"median":19.802914,"eighty":28.931965,"marketCap":3831644553},{"date":"2020-11-27","current":191.003299,"twenty":15.260409,"median":19.824132,"eighty":28.993533,"marketCap":4125671266},{"date":"2020-12-04","current":198.293707,"twenty":15.260409,"median":19.834923,"eighty":29.072788,"marketCap":4283144070},{"date":"2020-12-11","current":204.884666,"twenty":15.277405,"median":19.845593,"eighty":29.204431,"marketCap":4425508783},{"date":"2020-12-18","current":208.059087,"twenty":15.319129,"median":19.880269,"eighty":29.408025,"marketCap":4494076277},{"date":"2020-12-24","current":206.848503,"twenty":15.339718,"median":19.900532,"eighty":29.534806,"marketCap":4467927656},{"date":"2020-12-31","current":208.919947,"twenty":15.365764,"median":19.915811,"eighty":29.796111,"marketCap":4512670852},{"date":"2021-01-08","current":218.147289,"twenty":15.386249,"median":19.927575,"eighty":30.133245,"marketCap":4711981450},{"date":"2021-01-15","current":217.178822,"twenty":15.463133,"median":19.955186,"eighty":30.348098,"marketCap":4691062553},{"date":"2021-01-22","current":216.990509,"twenty":15.518993,"median":19.983043,"eighty":30.612845,"marketCap":4686994990},{"date":"2021-01-29","current":24.296226,"twenty":15.546124,"median":20.000911,"eighty":30.612845,"marketCap":4397616921},{"date":"2021-02-05","current":26.22567,"twenty":15.604175,"median":20.036867,"eighty":30.612845,"marketCap":4746846277},{"date":"2021-02-12","current":26.752174,"twenty":15.64869,"median":20.047071,"eighty":30.612845,"marketCap":4842143473},{"date":"2021-02-19","current":27.198418,"twenty":15.679949,"median":20.069656,"eighty":30.612845,"marketCap":4922913657},{"date":"2021-02-26","current":26.948508,"twenty":15.757032,"median":20.101665,"eighty":30.612845,"marketCap":4877680001},{"date":"2021-03-05","current":28.764142,"twenty":16.078184,"median":20.131636,"eighty":30.613864,"marketCap":5206309765},{"date":"2021-03-12","current":30.119103,"twenty":16.146147,"median":20.17181,"eighty":30.613864,"marketCap":5451557630},{"date":"2021-03-19","current":30.222173,"twenty":16.146147,"median":20.191936,"eighty":30.619304,"marketCap":5470213373},{"date":"2021-03-26","current":30.595804,"twenty":16.155113,"median":20.208951,"eighty":30.618171,"marketCap":5537840438},{"date":"2021-04-01","current":30.605466,"twenty":16.155113,"median":20.23058,"eighty":30.618171,"marketCap":5539589413},{"date":"2021-04-09","current":30.682769,"twenty":16.146147,"median":20.256725,"eighty":30.624072,"marketCap":5553581220},{"date":"2021-04-16","current":30.421872,"twenty":16.146147,"median":20.279169,"eighty":30.659957,"marketCap":5506358873},{"date":"2021-04-23","current":30.705316,"twenty":16.146147,"median":20.301119,"eighty":30.68362,"marketCap":5557662164},{"date":"2021-04-30","current":30.296255,"twenty":16.155113,"median":20.344302,"eighty":30.707893,"marketCap":5483622187},{"date":"2021-05-07","current":25.569844,"twenty":16.155113,"median":20.376409,"eighty":30.707893,"marketCap":5794126672},{"date":"2021-05-14","current":25.399722,"twenty":16.199938,"median":20.42789,"eighty":30.707893,"marketCap":5755577038},{"date":"2021-05-21","current":24.309395,"twenty":16.338001,"median":20.491036,"eighty":30.707893,"marketCap":5508508935},{"date":"2021-05-28","current":24.613553,"twenty":16.445582,"median":20.602521,"eighty":30.707893,"marketCap":5577431007},{"date":"2021-06-04","current":24.257843,"twenty":16.445582,"median":20.635149,"eighty":30.707893,"marketCap":5496827228},{"date":"2021-06-11","current":23.729434,"twenty":16.445582,"median":20.724193,"eighty":30.707893,"marketCap":5377089732},{"date":"2021-06-18","current":22.296285,"twenty":16.445582,"median":20.784488,"eighty":30.707893,"marketCap":5052338277},{"date":"2021-06-25","current":23.739744,"twenty":16.445582,"median":20.844829,"eighty":30.707893,"marketCap":5379426073},{"date":"2021-07-02","current":24.116075,"twenty":16.637435,"median":20.901381,"eighty":30.707893,"marketCap":5464702534},{"date":"2021-07-09","current":24.409922,"twenty":17.169936,"median":20.986777,"eighty":30.707893,"marketCap":5531288264},{"date":"2021-07-16","current":23.314439,"twenty":17.256001,"median":21.022105,"eighty":30.707893,"marketCap":5283051990},{"date":"2021-07-23","current":23.799029,"twenty":17.256001,"median":21.108637,"eighty":30.707893,"marketCap":5392860036},{"date":"2021-07-30","current":16.221256,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5679061858},{"date":"2021-08-06","current":16.529487,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5786973465},{"date":"2021-08-13","current":17.085494,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5981631539},{"date":"2021-08-20","current":16.514415,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5781696589},{"date":"2021-08-27","current":17.391968,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":6088928007},{"date":"2021-09-03","current":16.290002,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5703129776},{"date":"2021-09-10","current":15.723947,"twenty":15.757032,"median":21.108637,"eighty":30.707893,"marketCap":5504953785},{"date":"2021-09-17","current":15.378954,"twenty":15.742757,"median":21.108637,"eighty":30.707893,"marketCap":5384171968},{"date":"2021-09-24","current":15.594993,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5459807184},{"date":"2021-10-01","current":16.263207,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5693748664},{"date":"2021-10-08","current":16.043818,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5616940810},{"date":"2021-10-15","current":15.605042,"twenty":15.643409,"median":21.108637,"eighty":30.707893,"marketCap":5463325101},{"date":"2021-10-22","current":15.794285,"twenty":15.639757,"median":21.108637,"eighty":30.707893,"marketCap":5529579204},{"date":"2021-10-29","current":14.76593,"twenty":15.597281,"median":21.108637,"eighty":30.707893,"marketCap":6055507796},{"date":"2021-11-05","current":15.208034,"twenty":15.546124,"median":21.108637,"eighty":30.707893,"marketCap":6236814727},{"date":"2021-11-12","current":15.298251,"twenty":15.518993,"median":21.108637,"eighty":30.707893,"marketCap":6273812781},{"date":"2021-11-19","current":14.851461,"twenty":15.463133,"median":21.108637,"eighty":30.707893,"marketCap":6090584325},{"date":"2021-11-26","current":14.333071,"twenty":15.432575,"median":21.108637,"eighty":30.707893,"marketCap":5877992336},{"date":"2021-12-03","current":14.039507,"twenty":15.386249,"median":21.108637,"eighty":30.707893,"marketCap":5757601844},{"date":"2021-12-10","current":14.812797,"twenty":15.373275,"median":21.108637,"eighty":30.707893,"marketCap":6074728017},{"date":"2021-12-17","current":13.748807,"twenty":15.338429,"median":21.108637,"eighty":30.707893,"marketCap":5638385894},{"date":"2021-12-23","current":14.274358,"twenty":15.317813,"median":21.108637,"eighty":30.707893,"marketCap":5853914237},{"date":"2021-12-31","current":14.567922,"twenty":15.293897,"median":21.108637,"eighty":30.707893,"marketCap":5974304729},{"date":"2022-01-07","current":15.013279,"twenty":15.255263,"median":21.086933,"eighty":30.706604,"marketCap":6156945913},{"date":"2022-01-14","current":15.296819,"twenty":15.234158,"median":21.086933,"eighty":30.706604,"marketCap":6273225510},{"date":"2022-01-21","current":14.26147,"twenty":15.159469,"median":21.086933,"eighty":30.706604,"marketCap":5848628801},{"date":"2022-01-28","current":13.473236,"twenty":15.141331,"median":21.086933,"eighty":30.706604,"marketCap":5866246922},{"date":"2022-02-04","current":13.791554,"twenty":15.108005,"median":21.086933,"eighty":30.706604,"marketCap":6004842805},{"date":"2022-02-11","current":13.714672,"twenty":15.072408,"median":21.086933,"eighty":30.706604,"marketCap":5971368375},{"date":"2022-02-18","current":13.760532,"twenty":15.03684,"median":21.086933,"eighty":30.706604,"marketCap":5991335579},{"date":"2022-02-25","current":13.698487,"twenty":15.01748,"median":21.086933,"eighty":30.706604,"marketCap":5964321127},{"date":"2022-03-04","current":13.275413,"twenty":15.000697,"median":21.086933,"eighty":30.706604,"marketCap":5780114910},{"date":"2022-03-11","current":13.404745,"twenty":14.95296,"median":21.086933,"eighty":30.706604,"marketCap":5836425811},{"date":"2022-03-18","current":14.316596,"twenty":14.909849,"median":21.086933,"eighty":30.706604,"marketCap":6233446103},{"date":"2022-03-25","current":14.323128,"twenty":14.844637,"median":21.086933,"eighty":30.706604,"marketCap":6236290088},{"date":"2022-04-01","current":14.200329,"twenty":14.811668,"median":21.086933,"eighty":30.706604,"marketCap":6182823172},{"date":"2022-04-08","current":13.370779,"twenty":14.787157,"median":21.086933,"eighty":30.706604,"marketCap":5821637090},{"date":"2022-04-14","current":13.605352,"twenty":14.765711,"median":21.086933,"eighty":30.706604,"marketCap":5923770233},{"date":"2022-04-22","current":13.520383,"twenty":14.746344,"median":21.086933,"eighty":30.706604,"marketCap":5886774696},{"date":"2022-04-29","current":12.486253,"twenty":14.722676,"median":21.019089,"eighty":30.706604,"marketCap":5394061408},{"date":"2022-05-06","current":12.456696,"twenty":14.697062,"median":20.987955,"eighty":30.706604,"marketCap":5381292864},{"date":"2022-05-13","current":11.781959,"twenty":14.669658,"median":20.987955,"eighty":30.706604,"marketCap":5089806167},{"date":"2022-05-20","current":11.653499,"twenty":14.65307,"median":20.987955,"eighty":30.706604,"marketCap":5034311584},{"date":"2022-05-27","current":12.38533,"twenty":14.632214,"median":20.987955,"eighty":30.706604,"marketCap":5350462540},{"date":"2022-06-03","current":12.325642,"twenty":14.611294,"median":20.987955,"eighty":30.706604,"marketCap":5324677178},{"date":"2022-06-10","current":11.976595,"twenty":14.57907,"median":20.987955,"eighty":30.706604,"marketCap":5173888868},{"date":"2022-06-17","current":10.930751,"twenty":14.551074,"median":20.987955,"eighty":30.706604,"marketCap":4722084488},{"date":"2022-06-24","current":11.496493,"twenty":14.512301,"median":20.989133,"eighty":30.707893,"marketCap":4966484872},{"date":"2022-07-01","current":11.448483,"twenty":14.475592,"median":20.989133,"eighty":30.707893,"marketCap":4945744472},{"date":"2022-07-08","current":11.682046,"twenty":14.446312,"median":20.989133,"eighty":30.707893,"marketCap":5046643714},{"date":"2022-07-15","current":11.634035,"twenty":14.405366,"median":20.901381,"eighty":30.707893,"marketCap":5025903314},{"date":"2022-07-22","current":12.2945,"twenty":14.378471,"median":20.826627,"eighty":30.707893,"marketCap":5311223946},{"date":"2022-07-29","current":10.048078,"twenty":14.354753,"median":20.788925,"eighty":30.707893,"marketCap":5545534406},{"date":"2022-08-05","current":10.145269,"twenty":14.322523,"median":20.788925,"eighty":30.707893,"marketCap":5599173918},{"date":"2022-08-12","current":10.721601,"twenty":14.301896,"median":20.788925,"eighty":30.707893,"marketCap":5917251426},{"date":"2022-08-19","current":10.554902,"twenty":14.25908,"median":20.788925,"eighty":30.707893,"marketCap":5825250171},{"date":"2022-08-26","current":9.974504,"twenty":14.187553,"median":20.788925,"eighty":30.707893,"marketCap":5504928730},{"date":"2022-09-02","current":9.465258,"twenty":14.135304,"median":20.788925,"eighty":30.707893,"marketCap":5223876117},{"date":"2022-09-09","current":9.759015,"twenty":14.102002,"median":20.788925,"eighty":30.707893,"marketCap":5386000279},{"date":"2022-09-16","current":9.233506,"twenty":14.059394,"median":20.788925,"eighty":30.707893,"marketCap":5095971933},{"date":"2022-09-23","current":8.782199,"twenty":14.031264,"median":20.788925,"eighty":30.707893,"marketCap":4846895366},{"date":"2022-09-30","current":8.898075,"twenty":13.970918,"median":20.788925,"eighty":30.707893,"marketCap":4910847458},{"date":"2022-10-07","current":9.505917,"twenty":13.919195,"median":20.788925,"eighty":30.707893,"marketCap":5246315447},{"date":"2022-10-14","current":9.625859,"twenty":13.853034,"median":20.788925,"eighty":30.707893,"marketCap":5312511472},{"date":"2022-10-21","current":10.108676,"twenty":13.814554,"median":20.788925,"eighty":30.707893,"marketCap":5578978520},{"date":"2022-10-28","current":14.974971,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5630588980},{"date":"2022-11-04","current":15.463609,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5814316860},{"date":"2022-11-11","current":15.563653,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5851933626},{"date":"2022-11-18","current":15.647273,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5883374505},{"date":"2022-11-25","current":16.044465,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":6032718681},{"date":"2022-12-02","current":15.78614,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5935588822},{"date":"2022-12-09","current":14.866328,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5589739152},{"date":"2022-12-16","current":14.373571,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5404462543},{"date":"2022-12-23","current":14.855875,"twenty":13.814554,"median":20.344302,"eighty":30.707893,"marketCap":5585809042},{"date":"2022-12-30","current":14.999223,"twenty":13.814554,"median":19.765377,"eighty":30.707893,"marketCap":5639707692},{"date":"2023-01-06","current":15.569626,"twenty":13.814554,"median":19.464991,"eighty":30.682769,"marketCap":5854179403},{"date":"2023-01-13","current":16.083288,"twenty":13.814554,"median":19.115452,"eighty":30.607602,"marketCap":6047316232},{"date":"2023-01-20","current":16.159441,"twenty":13.814554,"median":18.427296,"eighty":30.461812,"marketCap":6075949889},{"date":"2023-01-27","current":15.870494,"twenty":13.814554,"median":17.1977,"eighty":30.416074,"marketCap":6365655133},{"date":"2023-02-03","current":16.700552,"twenty":13.814554,"median":17.005108,"eighty":30.370928,"marketCap":6698591585},{"date":"2023-02-10","current":16.651561,"twenty":13.814554,"median":16.756543,"eighty":30.27693,"marketCap":6678941035},{"date":"2023-02-17","current":16.851727,"twenty":13.814554,"median":16.756543,"eighty":30.179893,"marketCap":6759227566},{"date":"2023-02-24","current":16.526982,"twenty":13.814554,"median":16.695284,"eighty":30.105575,"marketCap":6628972495},{"date":"2023-03-03","current":17.355997,"twenty":13.814554,"median":16.651561,"eighty":29.955493,"marketCap":6961490255},{"date":"2023-03-10","current":15.566371,"twenty":13.814554,"median":16.584753,"eighty":29.755722,"marketCap":6243671220},{"date":"2023-03-17","current":15.480547,"twenty":13.814554,"median":16.531531,"eighty":29.517526,"marketCap":6209247509},{"date":"2023-03-24","current":14.869936,"twenty":13.814554,"median":16.458394,"eighty":29.346477,"marketCap":5964331266},{"date":"2023-03-31","current":15.968755,"twenty":13.81764,"median":16.370108,"eighty":29.233228,"marketCap":6405067639},{"date":"2023-04-06","current":16.098193,"twenty":13.814554,"median":16.263207,"eighty":29.165128,"marketCap":6456985367},{"date":"2023-04-13","current":16.098193,"twenty":13.811468,"median":16.213847,"eighty":29.047766,"marketCap":6456985367},{"date":"2023-04-21","current":11.256514,"twenty":13.795287,"median":16.167243,"eighty":28.957812,"marketCap":4514987632},{"date":"2023-04-28","current":10.547063,"twenty":13.769342,"median":16.098193,"eighty":28.929603,"marketCap":4230427133},{"date":"2023-05-05","current":9.97455,"twenty":13.75401,"median":16.098193,"eighty":28.929603,"marketCap":4000792069},{"date":"2023-05-12","current":10.85153,"twenty":13.72131,"median":16.043818,"eighty":28.869244,"marketCap":4360144650},{"date":"2023-05-19","current":10.855892,"twenty":13.715462,"median":15.968755,"eighty":28.809081,"marketCap":4361897590},{"date":"2023-05-26","current":10.676792,"twenty":13.696628,"median":15.930768,"eighty":28.764729,"marketCap":4289934926},{"date":"2023-06-02","current":10.354878,"twenty":13.660339,"median":15.878021,"eighty":28.764729,"marketCap":4160590154},{"date":"2023-06-09","current":11.276849,"twenty":13.620925,"median":15.820484,"eighty":28.752181,"marketCap":4531038118},{"date":"2023-06-16","current":11.224609,"twenty":13.575222,"median":15.789127,"eighty":28.740612,"marketCap":4510047958},{"date":"2023-06-23","current":11.398273,"twenty":13.554976,"median":15.774827,"eighty":28.742195,"marketCap":4579826058},{"date":"2023-06-30","current":12.275063,"twenty":13.534076,"median":15.748467,"eighty":28.744691,"marketCap":4932120371},{"date":"2023-07-07","current":12.273651,"twenty":13.517745,"median":15.73232,"eighty":28.744691,"marketCap":4931553069},{"date":"2023-07-14","current":12.851119,"twenty":13.480736,"median":15.69546,"eighty":28.744691,"marketCap":5163579436},{"date":"2023-07-21","current":13.091142,"twenty":13.444539,"median":15.669077,"eighty":28.744691,"marketCap":5260020713},{"date":"2023-07-28","current":28.047249,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5306539447},{"date":"2023-08-04","current":27.615476,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5224848012},{"date":"2023-08-11","current":26.895854,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5088695621},{"date":"2023-08-18","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":4907159099},{"date":"2023-08-25","current":26.047301,"twenty":13.437725,"median":15.657467,"eighty":28.735863,"marketCap":4928149259},{"date":"2023-09-01","current":27.32163,"twenty":13.437725,"median":15.657467,"eighty":28.633914,"marketCap":5169252452},{"date":"2023-09-08","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.427306,"marketCap":4907159099},{"date":"2023-09-15","current":26.131256,"twenty":13.437725,"median":15.657467,"eighty":28.310023,"marketCap":4944033705},{"date":"2023-09-22","current":25.732466,"twenty":13.437725,"median":15.657467,"eighty":28.103852,"marketCap":4868582588},{"date":"2023-09-29","current":26.778916,"twenty":13.437725,"median":15.657467,"eighty":28.040876,"marketCap":5066570857},{"date":"2023-10-06","current":25.921367,"twenty":13.437725,"median":15.657467,"eighty":27.952179,"marketCap":4904322591},{"date":"2023-10-13","current":26.404113,"twenty":13.437725,"median":15.657467,"eighty":27.770815,"marketCap":4995658153},{"date":"2023-10-20","current":25.186753,"twenty":13.437725,"median":15.657467,"eighty":27.598634,"marketCap":4765333692},{"date":"2023-10-27","current":17.482305,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5309375955},{"date":"2023-11-03","current":18.634591,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5659325216},{"date":"2023-11-10","current":18.896496,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5738865978},{"date":"2023-11-17","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-11-24","current":20.363168,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6184294245},{"date":"2023-12-01","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-12-08","current":19.455852,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5908742320},{"date":"2023-12-15","current":20.419291,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6201338694},{"date":"2023-12-22","current":21.33222,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6478595064},{"date":"2023-12-29","current":22.136644,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6722898833},{"date":"2024-01-05","current":21.592254,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6557567678},{"date":"2024-01-12","current":21.081538,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6402463192},{"date":"2024-01-19","current":21.749398,"twenty":13.417543,"median":15.643553,"eighty":27.632621,"marketCap":6605292135},{"date":"2024-01-26","current":21.257389,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6455869132},{"date":"2024-02-02","current":28.058844,"twenty":13.419632,"median":15.669077,"eighty":27.669555,"marketCap":7180258215},{"date":"2024-02-09","current":28.169854,"twenty":13.419632,"median":15.704121,"eighty":27.796495,"marketCap":7208665630},{"date":"2024-02-16","current":27.308418,"twenty":13.419632,"median":15.733099,"eighty":27.825797,"marketCap":6988224090},{"date":"2024-02-23","current":27.148564,"twenty":13.419632,"median":15.755466,"eighty":27.825797,"marketCap":6947317412},{"date":"2024-03-01","current":27.092062,"twenty":13.441726,"median":15.777181,"eighty":27.812943,"marketCap":6932858665},{"date":"2024-03-08","current":29.888075,"twenty":13.445242,"median":15.789127,"eighty":27.963376,"marketCap":7648358285},{"date":"2024-03-15","current":28.812755,"twenty":13.445242,"median":15.827779,"eighty":28.043716,"marketCap":7373184090},{"date":"2024-03-22","current":30.106708,"twenty":13.445242,"median":15.896443,"eighty":28.076477,"marketCap":7704306565},{"date":"2024-03-28","current":30.093322,"twenty":13.445242,"median":15.930965,"eighty":28.169854,"marketCap":7700881160},{"date":"2024-04-05","current":30.22941,"twenty":13.444539,"median":15.993577,"eighty":28.367293,"marketCap":7735706111},{"date":"2024-04-12","current":30.521665,"twenty":13.444539,"median":16.063876,"eighty":28.550678,"marketCap":7810494118},{"date":"2024-04-19","current":28.866298,"twenty":13.444539,"median":16.098193,"eighty":28.738359,"marketCap":7386885709},{"date":"2024-04-26","current":38.231767,"twenty":13.445242,"median":16.102434,"eighty":28.817217,"marketCap":8219830006},{"date":"2024-05-03","current":37.612546,"twenty":13.445242,"median":16.172772,"eighty":28.907655,"marketCap":8086697428},{"date":"2024-05-10","current":38.354269,"twenty":13.445242,"median":16.221256,"eighty":29.130483,"marketCap":8246167924},{"date":"2024-05-17","current":38.702534,"twenty":13.445242,"median":16.290002,"eighty":29.281518,"marketCap":8321044752},{"date":"2024-05-24","current":38.854069,"twenty":13.445242,"median":16.385606,"eighty":29.401797,"marketCap":8353624746},{"date":"2024-05-31","current":39.239552,"twenty":13.454387,"median":16.514415,"eighty":29.631749,"marketCap":8436503678},{"date":"2024-06-07","current":37.902323,"twenty":13.473236,"median":16.552178,"eighty":29.829217,"marketCap":8148999521},{"date":"2024-06-14","current":38.593535,"twenty":13.469601,"median":16.648062,"eighty":29.922236,"marketCap":8297610020},{"date":"2024-06-21","current":37.928908,"twenty":13.465967,"median":16.735546,"eighty":30.031355,"marketCap":8154715310},{"date":"2024-06-28","current":38.468585,"twenty":13.455063,"median":16.771844,"eighty":30.093322,"marketCap":8270745814},{"date":"2024-07-05","current":38.447317,"twenty":13.455063,"median":16.814111,"eighty":30.119103,"marketCap":8266173184},{"date":"2024-07-12","current":38.896605,"twenty":13.455063,"median":16.946902,"eighty":30.175867,"marketCap":8362770008},{"date":"2024-07-15","current":39.090676,"twenty":13.455063,"median":17.002596,"eighty":30.222173,"marketCap":8404495263},{"date":"2024-08-02","current":36.716509,"twenty":13.443132,"median":17.163621,"eighty":30.257604,"marketCap":8848678588},{"date":"2024-08-09","current":34.544426,"twenty":13.474636,"median":17.391968,"eighty":30.380644,"marketCap":8325206621},{"date":"2024-08-16","current":35.878536,"twenty":13.516412,"median":18.180924,"eighty":30.441623,"marketCap":8646727108},{"date":"2024-08-23","current":35.80732,"twenty":13.536427,"median":18.692584,"eighty":30.507515,"marketCap":8629564092},{"date":"2024-08-30","current":37.015615,"twenty":13.564424,"median":19.093862,"eighty":30.613864,"marketCap":8920763252},{"date":"2024-09-06","current":35.370529,"twenty":13.617967,"median":19.465206,"eighty":30.68362,"marketCap":8524297599},{"date":"2024-09-13","current":35.593672,"twenty":13.654447,"median":19.770139,"eighty":30.724008,"marketCap":8578075046},{"date":"2024-09-20","current":36.657162,"twenty":13.697093,"median":19.955344,"eighty":30.811628,"marketCap":8834376075},{"date":"2024-09-27","current":37.647062,"twenty":13.718449,"median":20.170481,"eighty":31.202877,"marketCap":9072941988},{"date":"2024-10-04","current":37.063092,"twenty":13.754547,"median":20.419291,"eighty":33.022546,"marketCap":8932205262},{"date":"2024-10-11","current":36.813837,"twenty":13.782708,"median":20.788925,"eighty":33.919642,"marketCap":8872134709},{"date":"2024-10-18","current":38.748534,"twenty":13.844231,"median":21.132049,"eighty":34.498848,"marketCap":9338396624},{"date":"2024-10-25","current":35.731356,"twenty":13.972834,"median":21.270485,"eighty":35.063709,"marketCap":8611256876},{"date":"2024-10-31","current":35.156674,"twenty":14.041756,"median":21.392084,"eighty":35.155808,"marketCap":9249721045},{"date":"2024-11-08","current":37.821894,"twenty":14.04673,"median":21.716135,"eighty":35.381924,"marketCap":9950940184},{"date":"2024-11-15","current":37.830595,"twenty":14.04673,"median":21.871932,"eighty":35.703819,"marketCap":9953229467},{"date":"2024-11-22","current":39.842745,"twenty":14.04673,"median":22.117001,"eighty":35.842453,"marketCap":10482626124},{"date":"2024-11-29","current":39.607813,"twenty":14.04673,"median":22.252579,"eighty":36.21515,"marketCap":10420815487},{"date":"2024-12-06","current":38.322212,"twenty":14.04673,"median":22.415358,"eighty":36.508084,"marketCap":10082573948},{"date":"2024-12-13","current":36.138213,"twenty":14.04673,"median":22.859046,"eighty":36.698326,"marketCap":9507963955},{"date":"2024-12-20","current":33.179809,"twenty":14.04673,"median":23.30284,"eighty":36.698326,"marketCap":8729607789},{"date":"2024-12-27","current":34.026,"twenty":14.04673,"median":23.434298,"eighty":36.698326,"marketCap":8952240545},{"date":"2025-01-03","current":32.842638,"twenty":14.04673,"median":23.518071,"eighty":36.698326,"marketCap":8640898079},{"date":"2025-01-10","current":33.425618,"twenty":14.045235,"median":23.729434,"eighty":36.704639,"marketCap":8794280029},{"date":"2025-01-17","current":33.814996,"twenty":14.045235,"median":23.80934,"eighty":36.704639,"marketCap":8896725436},{"date":"2025-01-24","current":35.437768,"twenty":14.045235,"median":23.953686,"eighty":36.704639,"marketCap":9323676686},{"date":"2025-01-31","current":33.333263,"twenty":14.045235,"median":23.956263,"eighty":36.531348,"marketCap":9823312666},{"date":"2025-02-07","current":33.556598,"twenty":14.045235,"median":23.956263,"eighty":36.222746,"marketCap":9889129548},{"date":"2025-02-14","current":32.746766,"twenty":14.045235,"median":23.956263,"eighty":35.878536,"marketCap":9650471812},{"date":"2025-02-21","current":33.306075,"twenty":14.045235,"median":23.956263,"eighty":35.814441,"marketCap":9815300176},{"date":"2025-02-28","current":31.197014,"twenty":14.045235,"median":23.956263,"eighty":35.764062,"marketCap":9193759885},{"date":"2025-03-07","current":29.524826,"twenty":14.045214,"median":23.954974,"eighty":35.772714,"marketCap":8700966306},{"date":"2025-03-14","current":29.365117,"twenty":14.045214,"median":23.967817,"eighty":35.772714,"marketCap":8653899927},{"date":"2025-03-21","current":29.877642,"twenty":14.045214,"median":24.116075,"eighty":35.772714,"marketCap":8804941148},{"date":"2025-03-28","current":30.412112,"twenty":14.045214,"median":24.170205,"eighty":35.772714,"marketCap":8962449399},{"date":"2025-04-04","current":28.45369,"twenty":14.045214,"median":24.30281,"eighty":35.772714,"marketCap":8385302378},{"date":"2025-04-11","current":27.414009,"twenty":14.045235,"median":24.43312,"eighty":35.764062,"marketCap":8078908592},{"date":"2025-04-17","current":27.614923,"twenty":14.045235,"median":24.592932,"eighty":35.764062,"marketCap":8138117897},{"date":"2025-04-25","current":29.14811,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":8589948135},{"date":"2025-05-02","current":27.818973,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9374993854},{"date":"2025-05-09","current":28.96729,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9761976856},{"date":"2025-05-16","current":30.05077,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10127109406},{"date":"2025-05-23","current":29.127679,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9816027974},{"date":"2025-05-30","current":29.564484,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9963231018},{"date":"2025-06-06","current":29.840899,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10056382944},{"date":"2025-06-13","current":31.878181,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10742947140},{"date":"2025-06-20","current":30.439799,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10258212117},{"date":"2025-06-27","current":32.052221,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10801598353},{"date":"2025-07-03","current":32.958248,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":11106929667},{"date":"2025-07-11","current":31.879888,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10743522152},{"date":"2025-07-18","current":32.303042,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10886125101},{"date":"2025-07-25","current":32.277448,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10877499923},{"date":"2025-08-01","current":32.02372,"twenty":14.045193,"median":24.891934,"eighty":35.443157,"marketCap":11265944866},{"date":"2025-08-08","current":31.84542,"twenty":14.045193,"median":24.891934,"eighty":35.35024,"marketCap":11203218811},{"date":"2025-08-15","current":31.240181,"twenty":14.045193,"median":24.891934,"eighty":35.144538,"marketCap":10990295503},{"date":"2025-08-20","current":31.405395,"twenty":14.045193,"median":24.891934,"eighty":34.721243,"marketCap":11048417811}],"updateTime":1755768542787},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531426716","title":"Crane 1Q Profit Soars on Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2531426716","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531426716?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:56","pubTimestamp":1745877360,"startTime":"0","endTime":"0","summary":"Crane produced a higher profit in the first quarter as its core sales increased and productivity efforts helped bolster the bottom line.The maker of industrial products posted a profit of $107.1 million, or $1.83 a share, compared with $64.8 million, or $1.12 a share, in the same period a year earlier.Stripping out one-time items, adjusted earnings were $1.39 a share. Analysts polled by FactSet had been expecting $1.31 a share.Sales rose 9% to $557.6 million, topping analyst forecasts for $548 million, according to FactSet.Most of that growth came from higher core sales, though acquisitions provided a boost as well. Higher productivity and volumes contributed to the jump in earnings, Crane said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0},{"id":"2531267163","title":"Crane Co reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2531267163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531267163?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:55","pubTimestamp":1745877303,"startTime":"0","endTime":"0","summary":"Crane Co reports results for the quarter ended March 31 - Earnings SummaryCrane Co CR.N reported quarterly adjusted earnings of $1.88 per share for the quarter ended March 31, higher than the same qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL8N3R62J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0},{"id":"2531268789","title":"Crane Holdings Q1 Adj. EPS $1.39 Beats $1.31 Estimate, Sales $557.60M Beat $547.96M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268789","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531268789?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:17","pubTimestamp":1745871453,"startTime":"0","endTime":"0","summary":"Crane Holdings (NYSE:CR) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.31 by 6.11 percent. This is a 24.11 percent increase over earnings of $1.12 per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45052774/crane-holdings-q1-adj-eps-1-39-beats-1-31-estimate-sales-557-60m-beat-547-96m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0},{"id":"2531268238","title":"BRIEF-Crane Company Q1 Sales USD 557.6 Million Vs. IBES Estimate USD 548 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268238","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531268238?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:15","pubTimestamp":1745871346,"startTime":"0","endTime":"0","summary":"BRIEF-Crane Company Q1 Sales USD 557.6 Million Vs. IBES Estimate USD 548 Million\n\n\nApr 28 (Reuters) - Crane Company outlook FY adjusted EPS USD 5.3-5.6.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nPLXE1ABE2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0},{"id":"2531558002","title":"Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531558002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531558002?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:38","pubTimestamp":1745861880,"startTime":"0","endTime":"0","summary":"90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*. NDV-01 showed promising clinical activity in BCG-nave and BCG-unresponsive patients, with favorable overall tolerability. Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 28, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point following treatment, demonstrating strong clinical activity and supporting further development of NDV-01 for the treatment of non-muscle invasive bladder cancer . The data were presented today at the American Urology Association 2025  Annual Meeting with a data cutoff date of April 20, 2025. To register for the virtual Investor Event, click here.Overall: The trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-presents-positive-initial-173800225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4161","RLMD","CR","ORR","BK4007","BK4139"],"gpt_icon":0},{"id":"2531912232","title":"CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2531912232","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531912232?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:14","pubTimestamp":1745853277,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc.  announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at the 2025 American Urological Association Annual Meeting.The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer  unresponsive to Bacillus Calmette Guerin  treatment with carcinoma in situ  with or without Ta or T1 disease.The study reported 75.5% complete response  at any time, with 34 confirmed CRs at 24 months and nine patients pending their 24-month assessment as of the March 14, 2025, cutoff date.Also Read: ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug. The 12—and 24-month CR rates are 50.7% and 42.3%, respectively, by K-M estimation.The median duration of response  is 28 months and ongoing. Notably, 97.3% of patients were free from progression to muscle-invasive disease at 24 months.Additionally, Cohort P, in patients with BCG-unresponsive Ta/T1 disease without CIS, showed an estimated 90.5% high-grade r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncologys-bladder-cancer-drug-151437058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4161","BK4139","IE00BGHQF748.EUR","CGON","IE00B3QW5Z07.USD","CG","BK4135","IE00B64PRP62.GBP","BK4211","ISBC","BCG"],"gpt_icon":0},{"id":"2530883352","title":"Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530883352","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530883352?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:01","pubTimestamp":1745838060,"startTime":"0","endTime":"0","summary":"Lynozyfic will provide a new option withconvenient dosing and administration to patients who face cycles of relapse and remission. TARRYTOWN, N.Y., April 28, 2025  -- Regeneron Pharmaceuticals, Inc.  today announced that the European Commission  has granted conditional marketing approval of Lynozyfic  to treat adults with relapsed and refractory (R/R) multiple myeloma . The indication is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. Lynozyfic is a bispecific antibody designed to bridge B-cell maturation antigen  on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.Lynozyfic is the first BCMAxCD3 therapy approved that can be dosed every four weeks due to a response-adapted regimen if a very good partial response  or better is achieved following completion of at lea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lynozyfic-linvoseltamab-approved-european-union-110100851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4201","LU0058720904.USD","EC","LU0053666078.USD","BK4585","REGN","LU0889565916.HKD","LU0823416689.USD","LU2362541513.USD","LU2106854487.HKD","LU2362540622.SGD","LU0114720955.EUR","LU2468319806.SGD","LU0289739699.SGD","LU2362541273.HKD","LU2237438978.USD","BK4161","BK4588","BK4139","ORR","CR","LU0109394709.USD","LU0882574055.USD","LU0320765992.SGD","LU1917777945.USD","LU2023250504.SGD","LU2089984988.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2530478698","title":"North American Morning Briefing: Stock Futures Fall Ahead of New Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2530478698","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530478698?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:01","pubTimestamp":1745834460,"startTime":"0","endTime":"0","summary":"Stock futures fell Monday on continued tariff uncertainty.Investors will get plenty of fresh data this week, including the first jobs report covering a period after Trump's Liberation Day tariffs announcement and an early readout on growth in the first three months of the year.Four of the Magnificent Seven tech stocks- Amazon, Apple, Meta Platforms and Microsoft -are set to headline a busy week for earnings.Spire Global completed the sale of its maritime business and used the proceeds to pay off debt. Shares rose 6.2%.WW International received a letter from an activist investor arguing against a chapter 11 bankruptcy filing. Activist investor Galloway Capital Partners said filing for bankruptcy wouldn't make sense. Shares climbed 168% before retreating 3% after the close.-Higher Treasury Yields Underscore a Problem for the National Debt. \"There's a possibility of another sell-off of Treasurys, and there's a high probability that U.S. import prices will rise, accelerating inflation, if ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMD","LU0724618433.USD","ARLP","LU0056508442.USD","ALRS","CR","ARE","GMGI","LU2750360641.GBP","BK4588","BK4144","EFSC","CCB","IE00B19Z3581.USD","LU2764263203.CNY","BMRC","LU2237443465.HKD","LU2471134952.CNY","LSBK","FMBM","LU1861219969.SGD","LU2764263039.SGD","IE0009356076.USD","BK4567","LU1323610961.USD","BK4085","CDNS","BKU","LU0094547139.USD","LU1852331112.SGD","IE00BN0W2V16.EUR","LU2471134879.HKD","BSBK","DPZ","ENSV","LU1721428347.USD","LU0354030438.USD","LU0353189763.USD","ET","NWBI","BK4223","LU1951198990.SGD","AFG","CFNB","BK4597","BRO","HTLF","LVO","BK4552"],"gpt_icon":0},{"id":"2530528324","title":"New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530528324","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530528324?lang=en_us&edition=fundamental","pubTime":"2025-04-28 01:00","pubTimestamp":1745773200,"startTime":"0","endTime":"0","summary":"New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association  2025 Annual Meeting in Las Vegas, Nevada. PRINCETON, N.J., April 27, 2025----UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer  that showed investigational drug UGN-102  for intravesical solution achieved robust and durable complete response  rates without negatively impacting quality of life. The data  were presented at the AUA 2025 Annual Meeting in Las Vegas, Nevada.In the Phase 2b OPTIMA II and Phase 3 ENVISION studies, patients received UGN-102, while in the Phase 3 ATLAS trial, patients were randomized to UGN-102 or trans-urethral resection of bladder tumor ; this analysis includes only data from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patient-reported-outcomes-ugn-102-170000688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4161","LU0124384867.USD","LU0256863811.USD","BK4585","LU0417517546.SGD","BK4588","LU1978683503.SGD","BK4139","IR","LU0256863902.USD","URGN","SG9999001440.SGD"],"gpt_icon":0},{"id":"2530454185","title":"New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530454185","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530454185?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:30","pubTimestamp":1745771400,"startTime":"0","endTime":"0","summary":"Data Presented at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada. PRINCETON, N.J., April 27, 2025----UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN102  for intravesical solution demonstrate clinically meaningful two-year duration of response  by Kaplan-Meier analysis. UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer .\"As the burden of LG-IR-NMIBC persists, the need for long-lasting treatment options becomes increasingly urgent,\" said Mark Schoenberg, Chief Medical Officer, UroGen. \"The growing body of evidence supporting UGN-102 underscores its potential to address this unmet need. These results emphasize UGN-102’s potential to deliver meaningful and sustained responses","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/long-term-data-optima-ii-163000202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["URGN","LU0256863902.USD","BK4161","LU1978683503.SGD","LU0124384867.USD","SG9999001440.SGD","LU0256863811.USD","CR","BK4139","IR","BK4588","LU0417517546.SGD","BK4585"],"gpt_icon":0},{"id":"2530033454","title":"Crane (CR) Q1 Earnings Report Preview: What To Look For","url":"https://stock-news.laohu8.com/highlight/detail?id=2530033454","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530033454?lang=en_us&edition=fundamental","pubTime":"2025-04-27 15:02","pubTimestamp":1745737320,"startTime":"0","endTime":"0","summary":"Industrial conglomerate Crane  will be reporting results tomorrow after market hours. Here’s what investors should know.Crane beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $544.1 million, up 12.3% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ organic revenue estimates but full-year EPS guidance missing analysts’ expectations.Looking at Crane’s peers in the general industrial machinery segment, some have already reported their Q1 results, giving us a hint as to what we can expect. GE Aerospace posted flat year-on-year revenue, missing analysts’ expectations by 7.9%, and 3M reported a revenue decline of 1%, topping estimates by 4.6%. GE Aerospace traded up 8.6% following the results while 3M was also up 8%.Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crane-cr-q1-earnings-report-070200772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR"],"gpt_icon":0},{"id":"2530171196","title":"CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530171196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530171196?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698200,"startTime":"0","endTime":"0","summary":"- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C –。- 58.3% of patients showed durable complete responses by K-M at 24 months –。- 97.3% of all treated patients remained free from progression to MIBC at 24 months–。- 91.6% of responders remained cystectomy-free at 24 months –。- No Grade 3 or greater treatment-related adverse events or deaths reported –。- Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M –。- Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 -. IRVINE, Calif., April 26, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-best-disease-201000079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","US12M.BOND","US2Y.BOND","CG","US10Y.BOND","BK4139","BK4588","US5Y.BOND","IE00B64PRP62.GBP","BK4161","US7Y.BOND","BK4135","BOND","BK4585","BK4117","IE00B3QW5Z07.USD","US3Y.BOND","US6M.BOND","BCG","CR","AFG","CGON","US30Y.BOND","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2530175941","title":"Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175941","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175941?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:50","pubTimestamp":1745689800,"startTime":"0","endTime":"0","summary":"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response  with more than half of responders remaining cancer-free at one year after CR. Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response  , meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response  was 25.8 months , indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 perc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1074936037.SGD","LU1061106388.HKD","LU1023059063.AUD","LU1244550221.USD","LU2592432038.USD","IE00BDGV0183.EUR","BK4504","IE00BLSP4239.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","BK4533","IE00B19Z3B42.SGD","IE00BN8TJ469.HKD","LU2505996509.AUD","RC","LU0466842654.USD","LU1066051811.HKD","IE00B1BXHZ80.USD","LU0203347892.USD","LU2347655156.SGD","LU2430703178.SGD","LU0882574055.USD","LU0792757196.USD","LU1894683264.USD","IE00B2B36J28.USD","LU0912757837.SGD","LU1914381329.SGD","JNJ","LU1059921491.USD","LU2468319806.SGD","LU1221951046.USD","LU1674673691.USD","LU0795875086.SGD","LU1929549753.HKD","OS","SG9999002232.USD","LU1244550577.SGD","LU1718418525.SGD","LU2129689431.USD","IE000M9KFDE8.USD","LU0234570918.USD","CR","IE00B7SZLL34.SGD","LU1244550494.USD","LU0345769128.USD","LU0114720955.EUR","LU0345769631.USD","LU1032955483.USD","BCG"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","BK4007","LU1883839398.USD","LU1894683348.USD","ADC","CI","BK4585","SG9999002224.SGD","SG9999003800.SGD","SG9999013999.USD","IE000M9KFDE8.USD","BK4592","BCG","CR","LU0985481810.HKD","IE0002270589.USD","LU0234572021.USD","SG9999001176.USD","SG9999011175.SGD","BK4534","OS","PFE","SOC","LU0225771236.USD","LU0321505439.SGD","LU1059921491.USD","LU0122379950.USD","LU1066053197.SGD","SGXZ57979304.SGD","BK4203","BK4231","LU0306806265.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","IE00BLSP4239.USD","BK4550","LU0456855351.SGD","BK4135","SG9999002232.USD","LU1023059063.AUD","BK4588","BK4097","BK4581","LU0289739699.SGD","LU1057294990.SGD","LU0170899867.USD","BK4213","BK4533","HR"],"gpt_icon":1},{"id":"2530685901","title":"ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530685901","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530685901?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:10","pubTimestamp":1745601000,"startTime":"0","endTime":"0","summary":"- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide  was well-tolerated and demonstrated promising anti-tumor activity. - Combination generated complete responses  in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma  comparing favorably to 34% historical CR rate with R2 alone. - Phase 2 portion of trial in patients with previously untreated indolent NHL  is ongoing and has completed enrollment. After a median follow-up of 28 months  the two-year progression-free survival  rate was 69% and two-year overall survival  rate was 84%. Sixteen patients (80%) achieved complete responses and the best overall response rate  was 90%. As previously repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-announces-encouraging-final-171000715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","SMP","BK4139","ALX","BK4124","ALXO","BK4161","BK4211","BK4231","CR","PFS","ORR","OS","BK4097","BK4080"],"gpt_icon":0},{"id":"2529937050","title":"1 Profitable Stock on Our Watchlist and 2 to Brush Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2529937050","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529937050?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:05","pubTimestamp":1745499948,"startTime":"0","endTime":"0","summary":"While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here is one profitable company that balances growth and profitability and two best left off your watchlist.Founded in 1883, Wolverine Worldwide  is a global footwear company with a diverse portfolio of brands including Merrell, Hush Puppies, and Saucony.Annual revenue declines of 5% over the last five years indicate problems with its market positioning. Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable. Negative returns on capital show that some of its growth strategies have backfired. Earnings per share have contracted by 4.1% annually over the last five year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/1-profitable-stock-watchlist-2-130548534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRNS","CR","BK4146","BK4104","BK4161","WWW"],"gpt_icon":0},{"id":"2529818619","title":"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529818619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529818619?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif, April 24, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute  at Colorado Blood Cancer Institute  in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CR","BK4161","ORR","PK","CEROW","CERO","BK4218","BK4181"],"gpt_icon":0},{"id":"2529875483","title":"Allegion Gears Up to Post Q1 Earnings: Here's What to Expect","url":"https://stock-news.laohu8.com/highlight/detail?id=2529875483","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529875483?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:23","pubTimestamp":1745245380,"startTime":"0","endTime":"0","summary":"Factors Likely to Have Shaped ALLE’s Quarterly Performance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allegion-gears-post-q1-earnings-142300441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["POST","CR","ITW","ALLE"],"gpt_icon":0},{"id":"2527016153","title":"Crane Company (CR) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2527016153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527016153?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:16","pubTimestamp":1744629410,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Nathan Jones maintained a Hold rating on Crane Company (CR – Research Report) today and set a price target of $144.00. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crane-company-cr-receives-a-rating-update-from-a-top-analyst-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crane-company-cr-receives-a-rating-update-from-a-top-analyst-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR"],"gpt_icon":0},{"id":"2526514375","title":"Crane, Kennametal, International Paper, Lennar, and KB Home Shares Plummet, What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526514375","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526514375?lang=en_us&edition=fundamental","pubTime":"2025-04-11 01:11","pubTimestamp":1744305065,"startTime":"0","endTime":"0","summary":"A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.Also President Trump indicated he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression . For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets.The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.Access our full analysis report here, it’s free.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crane-kennametal-international-paper-lennar-171105108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4504","IE00B3T34201.USD","CR","LU1169589451.USD","BK4588","BK4585","LU1481599808.USD","LU1481600234.SGD","LEN","BK4088","KMT","BK4136","LU2463526074.USD","BK4596","LU1169590202.USD","LU1487256676.USD","KB","KBH","LU0314104364.USD","BK4207","BK4559","IP"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":160,"code":"91000000","status":"200"}]}}